Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Metastatic Uveal Melanoma
DRUG: Binimetinib|DRUG: Belinostat
Overall Response Rate, Overall Response Rate (ORR) defined as proportion of patients to have achieved a complete or partial response per RECIST v1.1 criteria., Up to 5 years
Progression Free Survival, Progression Free Survival (PFS) is defined as the length of time from start of study treatment to the earlier of the first documentation of disease progression or death from any cause., Up to 5 years|Overall Survival, Overall Survival (OS) is defined as the length of time from start of treatment to date of death from any cause., Up to 5 years
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.